Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

‘Off-label’ drug use in sexual medicine treatment

International Journal of Impotence Research volume 20, pages 127–134 (2008)Cite this article

Abstract

Phosphodiesterase type 5 inhibitors are the only drugs approved for a specific sexual function disorder. All other drugs used in the treatment of sexual disorders are used ‘off-label.’ This paper reviews the use of drugs in the treatment of premature ejaculation, Peyronie's disease and female hypoactive sexual desire disorder (HSDD). While the treatment of premature ejaculation is quite well documented and supported by evidence of good quality in the medical literature, there is little evidence for the use of the variety of medications in use for the treatment of Peyronie's disease. In particular, the use of verapamil is not supported by any double-blind studies whatsoever. The use of testosterone patch for treatment of HSDD in postmenopausal women is well documented, but not in premenopausal women.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. US Food and Drug Administration. ‘Off-label’ and investigational use of marketed drugs, biologics, and medical devices. http://www.fda.gov/oc/ohrt/irbs/offlabel.html.

  2. Radley DC, Finkelstein SN, Stafford RS . Off-label prescribing among office-based physicians. Arch Intern Med 2006; 166: 1021–1026.

    Article  Google Scholar 

  3. Dooley AG . Off-label drug use. Med Health RI 2007; 90: 63–65.

    Google Scholar 

  4. Plaza CI . Health insurance oversight issue brief; mandated benefits: off-label drug coverage requirements: (year end report—2004). Issue Brief Health Policy Track Serv 2004; 1–9.

  5. Henry V . Off-label prescribing: legal implications. J Leg Med 1999; 20: 365–384.

    Article  CAS  Google Scholar 

  6. Waldinger MD, Berendsen HH, Blok BF, Olivier B, Holstege G . Premature ejaculation and serotonergic antidepressants-induced delayed ejaculation: the involvement of the serotonergic system. Behav Brain Res 1998; 92: 111–118.

    Article  CAS  Google Scholar 

  7. Waldinger MD, Hengeveld MW, Zwinderman AH . Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study. Am J Psychiatry 1994; 1377–1379.

  8. Waldinger MD, Zwinderman AH, Schweitzer DH, Olivier B . Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. Int J Impot Res 2004; 16: 369–381.

    Article  CAS  Google Scholar 

  9. Athanasios Z, Polyanthi P, George K . The efficacy of duloxetine in the treatment of premature ejaculation. Int Urol Nephrol 2007; 39: 115–118.

    Article  CAS  Google Scholar 

  10. Arafa M, Shamloul R . Efficacy of sertraline hydrochloride in treatment of premature ejaculation: a placebo-controlled study using a validated questionnaire. Int J Impot Res 2006; 18: 534–538.

    Article  CAS  Google Scholar 

  11. Pryor JL, Althof SE, Steidle C, Rosen RC, Hellstrom WJ, Shabsigh R . et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet 2006; 368: 929–937.

    Article  CAS  Google Scholar 

  12. Shabsigh R, Pryor J, Tesfaye F . Dapoxetine for the treatment of premature ejaculation: low incidence of sexual side effects. Abstract P-05-041 9th Congress of the European Society of Sexual Medicine 2006.

  13. Salem EA, Wilson SK, Bissada NK, Delk JR, Hellstrom WJ, Cleves MA . Tramadol HCl has promise in on-demand use to treat premature ejaculation. J Sex Med 2007; e-pub ahead of print: 14 March 2007.

  14. Busato W, Galindo CC . Topical anaesthetic use for treating premature ejaculation: a double-blind, randomized, placebo-controlled study. BJU Int 2004; 93: 1018–1021.

    Article  CAS  Google Scholar 

  15. Dinsmore WW, Hackett G, Goldmeier D, Waldinger M, Dean J, Wright P et al. Topical eutectic mixture for premature ejaculation (tempe): a novel aerosol-delivery form of lidocaine–prilocaine for treating premature ejaculation. BJU Int 2006; 99: 369–375.

    Article  Google Scholar 

  16. Atan A, Basar MM, Tuncel A, Ferhat M, Agras K, Tekdogan U . Comparison of efficacy of sildenafil-only, sildenafil plus topical EMLA cream, and topical EMLA- cream- only in treatment of premature ejaculation. Urology 2006; 67: 388–391.

    Article  Google Scholar 

  17. Abdel-Hamid IA, El Naggar EA, El Gilany A-H . Assessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation. Int J Impot Res 2001; 13: 41–45.

    Article  CAS  Google Scholar 

  18. McMahon CG, Stuckey BG, Andersen M, Purvis K, Koppiker S, Haughie S et al. Efficacy of sildenafil citrate (Viagra) in men with premature ejaculation. J Sex Med 2005; 2: 368–375.

    Article  CAS  Google Scholar 

  19. McMahon CG, McMahon CN, Leow LJ, Winestock CG . Efficacy of type-5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: a systematic review. BJU Int 2006; 98: 259–272.

    Article  CAS  Google Scholar 

  20. Gelbard MK, Dorey F, James K . The natural history of Peyronie's disease. J Urol 1990; 144: 1376–1379.

    Article  CAS  Google Scholar 

  21. Weidner W, Hauck EW, Schnitker J . Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. Eur Urol 2005; 47: 530–535.

    Article  CAS  Google Scholar 

  22. Martin DJ, Badwan K, Parker M, Mulhall JP . Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol 2002; 168: 2483–2485.

    Article  CAS  Google Scholar 

  23. Levine LA, Estrada CR, Shou W, Cole A . Tunica albuginea tissue analysis after electromotive drug administration. J Urol 2003; 169: 1775–1778.

    Article  CAS  Google Scholar 

  24. Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Giuriolo A, Jannini EA et al. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. J Urol 2004; 171: 1605–1608.

    Article  CAS  Google Scholar 

  25. Fitch III WP, Easterling WJ, Talbert RL, Bordovsky MJ, Mosier M . Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie' disease- a placebo-controlled pilot study. J Sex Med 2007; 4: 477–484.

    Article  CAS  Google Scholar 

  26. Lamprakopoulos A, Zorzos I, Lykourinas M . The use of betamethasone and hyaluronidase injections in the treatment of Peyronie's disease. Scand J Urol Nephrol 2000; 34: 355–360.

    Article  CAS  Google Scholar 

  27. Gelbard MK, James K, Riach P, Dorey F . Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study. J Urol 1993; 149: 56–58.

    Article  CAS  Google Scholar 

  28. Duncan MR, Berman B, Nseyo UO . Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol 1991; 25: 89–94.

    Article  CAS  Google Scholar 

  29. Wegner HE, Andresen R, Knispel HH, Miller K . Local interferon-alpha 2b is not an effective treatment in early-stage Peyronie's disease. Eur Urol 1997; 32: 190–193.

    CAS  PubMed  Google Scholar 

  30. Judge IS, Wisniewski ZS . Intralesional interferon in the treatment of Peyronie's disease: a pilot study. Br J Urol 1997; 79: 40–42.

    Article  CAS  Google Scholar 

  31. Inal T, Tokatli Z, Akand M, Ozdiler E, Yaman O . Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: a randomized and prospective study.

  32. Hellstrom WJ, Kendirci M, Matern R, Cockerham Y, Myers L, Sikka SC et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon α-2b for minimally invasive treatment for Peyronie's disease. J Urol 2006; 176: 394–398.

    Article  CAS  Google Scholar 

  33. Levine LA, Merrick PF, Lee RC . Intralesional verapamil injection for the treatment of Peyronie's disease. J Urol 1994; 151: 1522–1524.

    Article  CAS  Google Scholar 

  34. Levine LA, Goldman KE, Greenfield JM . Experience with intraplaque injection of verapamil for Peyronie's disease. J Urol 2002; 168: 621–625.

    Article  CAS  Google Scholar 

  35. Rehman J, Benet A, Melman A . Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study. Urology 1998; 51: 620–626.

    Article  CAS  Google Scholar 

  36. Bennett NE, Guhring P, Mulhall JP . Intralesional verapamil prevents the progression of Peyronie's disease. Urology 2007; 1181–1184.

    Article  Google Scholar 

  37. Russell S, Steers W, McVary KT . Systematic evidence-based analysis of plaque injection therapy for Peyronie's disease. Eur Urol 2007; 51: 601–603.

    Article  Google Scholar 

  38. Laumann EO, Paik A, Rosen RC . Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281: 537–544.

    Article  CAS  Google Scholar 

  39. Basson R, Berman J, Burnett A, Derogatis L, Ferguson D, Fourcroy J et al. Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J Urol 2000; 163: 888–893.

    Article  CAS  Google Scholar 

  40. Bachmann G, Bancroft J, Braunstein G, Burger H, Davis S, Dennerstein L et al. Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril 2002; 77: 660–665.

    Article  Google Scholar 

  41. Guay A, Munarriz R, Jacobson J, Talakoub L, Traish A, Quirk F et al. Serum androgen levels in healthy premenopausal women with and without sexual dysfunction: Part A. Serum androgen levels in women aged 20–49 years with no complaints of sexual dysfunction. Int J Impot Res 2004; 16: 112–120.

    Article  CAS  Google Scholar 

  42. Davison SL, Bell R, Donath S, Montalto JG, Davis SR . Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005; 90: 3847–3853.

    Article  CAS  Google Scholar 

  43. Lobo RA, Rosen RC, Yang HM, Block B, Van Der Hoop RG . Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil Steril 2003; 79: 1341–1352.

    Article  Google Scholar 

  44. Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Eng J Med 2000; 343: 682–688.

    Article  CAS  Google Scholar 

  45. Braunstein GD, Sundwall DA, Katz M, Shifren JL, Buster JE, Simon JA et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med 2005; 165: 1582–1589.

    Article  CAS  Google Scholar 

  46. Davis SR, van der Mooren MJ, van Lunsen RH, Lopes P, Ribot C, Rees M et al. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause 2006; 13: 387–396.

    Article  Google Scholar 

  47. Wierman ME, Basson R, Davis SR, Khosia S, Miller KK, Rosner W et al. Androgen therapy in women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006; 91: 3697–3710.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Iowa, IA, USA

    B Fallon

Authors
  1. B Fallon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B Fallon.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fallon, B. ‘Off-label’ drug use in sexual medicine treatment. Int J Impot Res 20, 127–134 (2008). https://doi.org/10.1038/sj.ijir.3901610

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901610

Keywords

This article is cited by

Search

Advanced search

Quick links